Following a review of available data, the European Medicines Agency recommended changes to the product information for zolpidem-containing medicines to minimise the known risk of reduced mental alertness and impaired ability to drive and use machinery the morning after use. These changes include strengthened warnings and precautions, as outlined by the MHRA in a related Drug Safety Update article issued in May 2014 (see link below).